US1101221083
US1101221083
Bristol-Myers Squibb Company
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 120.77B EUR | 117.64B EUR | 123.83B EUR | 109.81B EUR |
Enterprise Value | 155.69B EUR | 153.98B EUR | 160.69B EUR | 146.74B EUR |
Valuation Multiples | ||||
Trailing P/E | 13.02x | 12.67x | 17.02x | 23.88x |
Forward P/E | 8.94x | -- | -- | -- |
Price to Sales | 2.46x | 2.39x | 2.55x | 2.97x |
Price to Book | 5.41x | 5.27x | 6.17x | 5.94x |
EV/Revenue | 3.17x | 3.13x | 3.31x | 3.97x |
EV/EBITDA | 8.23x | 8.28x | 8.44x | 9.85x |
Price to FCF (P/FCF) | 14.88x | 10.28x | 10.4x | 9.85x |
EV/FCF | 19.19x | 13.46x | 13.49x | 13.16x |
FCF Yield | 6.72% | 9.72% | 9.62% | 10.15% |